Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
Authors:
- Marta Alonso-PeñaMAMarta Alonso-Peña
- Maria Del BarrioMBMaria Del Barrio
- Ana Peleteiro-VigilAPAna Peleteiro-Vigil
- Carolina Jimenez-GonzalezCJCarolina Jimenez-Gonzalez
- Alvaro Santos-LasoASAlvaro Santos-Laso
- Maria Teresa Arias-LosteMAMaria Teresa Arias-Loste
- Paula IruzubietaPIPaula Iruzubieta
- Javier CrespoJCJavier Crespo
Open Access
- 27 June 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10718
Abstract
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis may result from the dysfunction of multiple pathways and thus multiple molecular triggers involved in the disease have been described. The development of NASH entails the activation of inflammatory and fibrotic processes. Furthermore, NAFLD is also strongly associated with several extra-hepatic comorbidities, i.e., metabolic syndrome, type 2 diabetes mellitus, obesity, hypertension, cardiovascular disease and chronic kidney disease. Due to the heterogeneity of NAFLD presentations and the multifactorial etiology of the disease, clinical trials for NAFLD treatment are testing a wide range of interventions and drugs, with little success. Here, we propose a narrative review of the different phenotypic characteristics of NAFLD patients, whose disease may be triggered by different agents and driven along different pathophysiological pathways. Thus, correct phenotyping of NAFLD patients and personalized treatment is an innovative therapeutic approach that may lead to better therapeutic outcomes.Keywords
This publication has 221 references indexed in Scilit:
- Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidityHPB, 2012
- Human immunodeficiency virus (HIV)‐1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein‐1 expressionHepatology, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Heritability of Nonalcoholic Fatty Liver DiseaseGastroenterology, 2009
- Nonalcoholic Fatty Liver Disease Among HIV-Infected PersonsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- A core gut microbiome in obese and lean twinsNature, 2008
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver DiseaseGastroenterology, 2008
- The lipin protein family: Dual roles in lipid biosynthesis and gene expressionFEBS Letters, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005